August 15, 2007
Proteolix starts clinical trial of multiple myeloma drug
The South San Francisco drug company is running the test with the Multiple Myeloma Research Consortium at 10 centers associated with the consortium. Centers participating in the Phase II trial include Emory University, the Mayo Clinic, the University of Michigan and Washington University. Patients enrolled in the study will have relapsed and refractory multiple myeloma -- meaning their cancer has reappeared after they were treated with at least two other FDA-approved therapies and that their cancer is resistant to treatment.
Multiple myeloma is an incurable cancer of the plasma cells, part of the immune system.
The Multiple Myeloma Research Foundation is based in Norwalk, Conn., and was founded in 1998 by twin sisters, Karen Andrews and Kathy Giusti, one of whom had the disease. Giusti, who is president of the foundation, founded the consortium -- a nonprofit group to coordinate academic centers for myeloma research.
Article Link
© 2007 American City Business Journals Inc. All rights reserved.
